OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+19.4%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$334M
AUM Growth
+$334M
(+16%)
Cap. Flow
+$20.1M
Cap. Flow
% of AUM
6.03%
Top 10 Holdings %
Top 10 Hldgs %
61.83%
Holding
47
New
7
Increased
16
Reduced
9
Closed
6
Top Buys
| 1 |
Karyopharm Therapeutics
KPTI
|
$6.24M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
$5.52M |
| 3 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$5.33M |
| 4 |
Theravance Biopharma
TBPH
|
$4.98M |
| 5 |
IDEAYA Biosciences
IDYA
|
$2.8M |
Top Sells
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
$3.37M |
| 2 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$3.23M |
| 3 |
Mersana Therapeutics
MRSN
|
$2.7M |
| 4 |
Fennec Pharmaceuticals
FENC
|
$2.61M |
| 5 |
BioAtla
BCAB
|
$2.16M |
Sector Composition
| 1 | Healthcare | 98.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $79.9M | 23.92% |
3,775,000
| – | – |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $32.2M | 9.64% |
6,105,900
+30,900
| +0.5% | +$163K |
|
3
TELA Bio
TELA
$70.5M
| $22.1M | 6.61% |
2,072,813
| – | – |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $13.1M | 3.93% |
735,000
| – | – |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12.6M | 3.78% |
785,794
+53,794
| +7% | +$864K |
|
|
6
Karyopharm Therapeutics
KPTI
$61.7M
| $10.9M | 3.27% |
2,810,800
+1,603,959
| +133% | +$6.24M |
|
7
Keros Therapeutics
KROS
$618M
| $10.2M | 3.04% |
238,000
| – | – |
|
|
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $9M | 2.7% |
4,764,508
+174,508
| +4% | +$330K |
|
9
Eton Pharmaceutcials
ETON
$464M
| $8.41M | 2.52% |
2,185,000
+15,000
| +0.7% | +$57.8K |
|
10
Protara Therapeutics
TARA
$120M
| $8.08M | 2.42% |
2,692,594
| – | – |
|
11
Biohaven
BHVN
$1.63B
| $7.38M | 2.21% |
540,000
| – | – |
|
12
Cytokinetics
CYTK
$4.23B
| $7.3M | 2.19% |
207,500
-42,500
| -17% | -$1.5M |
|
13
KalVista Pharmaceuticals
KALV
$678M
| $7.26M | 2.17% |
923,200
| – | – |
|
14
Vaxcyte
PCVX
$4B
| $6.63M | 1.99% |
177,000
| – | – |
|
15
Larimar Therapeutics
LRMR
$310M
| $6.35M | 1.9% |
1,401,000
-159,000
| -10% | -$720K |
|
|
16
Theravance Biopharma
TBPH
$699M
| $5.93M | 1.78% |
546,304
+458,704
| +524% | +$4.98M |
|
|
17
Arcutis Biotherapeutics
ARQT
$1.86B
| $5.52M | 1.65% |
+502,000
| New | +$5.52M |
|
18
4D Molecular Therapeutics
FDMT
$288M
| $5.4M | 1.62% |
314,000
-16,000
| -5% | -$275K |
|
|
JNCE
19
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $5.33M | 1.6% |
+2,880,000
| New | +$5.33M |
|
|
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.28M | 1.58% |
765,000
-61,200
| -7% | -$422K |
|
21
Xoma
XOMA
$392M
| $5.13M | 1.54% |
243,000
| – | – |
|
22
Edgewise Therapeutics
EWTX
$1.51B
| $5M | 1.5% |
750,000
+138,600
| +23% | +$924K |
|
|
MOR
23
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $4.73M | 1.42% |
1,194,000
+297,400
| +33% | +$1.18M |
|
|
24
IDEAYA Biosciences
IDYA
$2.15B
| $4.71M | 1.41% |
343,000
+204,200
| +147% | +$2.8M |
|
25
UroGen Pharma
URGN
$900M
| $4.67M | 1.4% |
505,000
+16,344
| +3% | +$151K |
|